Letter abstract


Nature Cell Biology 10, 1208 - 1216 (2008)
Published online: 21 September 2008 | doi:10.1038/ncb1781

Jade-1 inhibits Wnt signalling by ubiquitylating bold beta-catenin and mediates Wnt pathway inhibition by pVHL

Vipul C. Chitalia1, Rebecca L. Foy1, Markus M. Bachschmid2, Liling Zeng1, Maria V. Panchenko1, Mina I. Zhou1, Ajit Bharti3, David C. Seldin4, Stewart H. Lecker5, Isabel Dominguez4 & Herbert T. Cohen1,4

Top

The von Hippel–Lindau protein pVHL suppresses renal tumorigenesis in part by promoting the degradation of hypoxia-inducible HIF-alpha transcription factors1; additional mechanisms have been proposed2. pVHL also stabilizes the plant homeodomain protein Jade-1, which is a candidate renal tumour suppressor that may correlate with renal cancer risk3, 4, 5. Here we show that Jade-1 binds the oncoprotein beta-catenin in Wnt-responsive fashion. Moreover, Jade-1 destabilizes wild-type beta-catenin but not a cancer-causing form of beta-catenin. Whereas the well-established beta-catenin E3 ubiquitin ligase component beta-TrCP ubiquitylates only phosphorylated beta-catenin6, Jade-1 ubiquitylates both phosphorylated and non-phosphorylated beta-catenin and therefore regulates canonical Wnt signalling in both Wnt-off and Wnt-on phases. Thus, the different characteristics of beta-TrCP and Jade-1 may ensure optimal Wnt pathway regulation. Furthermore, pVHL downregulates beta-catenin in a Jade-1-dependent manner and inhibits Wnt signalling, supporting a role for Jade-1 and Wnt signalling in renal tumorigenesis. The pVHL tumour suppressor and the Wnt tumorigenesis pathway are therefore directly linked through Jade-1.

Top
  1. Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
  2. Vascular Biology Unit, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
  3. Molecular Stress Response Unit, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
  4. Hematology–Oncology Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
  5. Renal Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02118, USA.

Correspondence to: Herbert T. Cohen1,4 e-mail: htcohen@bu.edu



MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

One hit, two outcomes for VHL-mediated tumorigenesis

Nature Cell Biology News and Views (01 Oct 2008)


Extra navigation

Subscribe to Nature Cell Biology

Subscribe

Open Innovation Challenges